Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aldeyra Therapeutics, Inc.
< Previous
1
2
3
Next >
Aldeyra Therapeutics Announces Chief Financial Officer Transition
April 28, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
April 27, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 21, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
April 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
March 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
March 22, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
February 01, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
January 11, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
January 06, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
January 04, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
December 20, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Upcoming Conferences
November 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
November 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
November 02, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
October 28, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
October 21, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
September 02, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
August 05, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
August 04, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
August 03, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
July 29, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
July 20, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
July 01, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
May 06, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
April 29, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
April 28, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
April 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
April 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.